Results for ret translation from English to Maltese

ret mutation status
stat mutazzjonali ret

ret mutation status in study 58
stat tal-mutazzjoni ret fi studju 58

rearranged during transfection (ret) status
stat irranġat mill-ġdid waqt it-transfezzjoni (ret)

patients with documented ret mutation (n=187)
pazjenti b’mutazzjoni ret dokumentata (n=187)

there was no improvement in os for the ret m918t negative and unknown subgroups.
ma kienx hemm titjib fl-os għall-ret m918t negattiva u sottogruppi negattivi u mhux magħrufa.

determination of ret status should be made preferably just prior to the initiation of treatment.
l-istat tal-ret għandu jiġi determinat l-aħjar eżatt qabel ma tinbeda l-kura.

for an additional 115 subjects the ret mutational status could not be determined or was unclear.
għal 115-il individwu ieħor l- istat mutazzjonali ret ma setgħax jiġi stabbilit jew ma kienx ċar.

patients will not be required to have a fresh tissue biopsy to determine ret status before enrolment.
il-pazjenti mhux ser ikollhom jgħamlu bajopsi tat-tessut mill-ġdid sabiex jiġi stabbilit l-istat ret qabel jiddaħlu.

efficacy with cabozantinib was observed in medullary thyroid cancer patients with wild-type or mutant ret.
l-effikaċja b’cabozantinib ġiet osservata f’pazjenti b’kanċer fil-medulla tat-tirojdi b’ret wild-type jew mutanti.

in addition, ret mutation negative patients who do not receive vandetanib due to ret status or contraindication will be allowed to enrol and followed.
minbarra hekk, pazjenti b’mutazzjoni ret negattiva li ma jirċievux vandetanib minħabba l-istat ret jew kontraindikazzjoni ser jitħallew jidħlu u jiġu segwiti.

a patient was considered to have a ret mutation if either an m918t mutation by the arms assay, or a ret mutation in any exons sequenced was present in the tumour.
pazjent kien meqjus li għandu mutazzjoni ret jekk il- mutazzjoni m918t permezz tal-essej arms fi kwalunkwe ekson kien preżenti fit-tumur.

(e)the yield strength 'ret' is the value at the maximum working temperature tmax
is-saħħa ta' li joħroġ ‘ret' hija l-valur fit-temperatura massima operattiva tmass

for patients whose ret mutation status could be negative, a possible lower benefit should be taken into account before individual treatment decisions and the use of vandetanib should be carefully considered because of the treatment related risks.
għall-pazjenti li jista’ jkollhom stat ret negattiv, il-fatt li l-benefiċċju jista’ jkun aktar baxx għandu jitqies qabel jittieħdu deċiżjonijiet dwar il-kura individwali u l-użu ta’ vandetanib għandu jiġi ikkonsidrat minħabba r-riskji relatati mal-kura.

sunitinib was identified as an inhibitor of platelet-derived growth factor receptors (pdgfrα and pdgfrβ), vascular endothelial growth factor receptors (vegfr1, vegfr2 and vegfr3), stem cell factor receptor (kit), fms-like tyrosine kinase-3 (flt3), colony stimulating factor receptor (csf-1r), and the glial cell-line derived neurotrophic factor receptor (ret).
sunitinib kien identifikat bħala impeditur ta’ riċettaturi tal-fatturi ta’ l-iżvilupp li ġejjin mill-plejtlits (pdgfrα u pdgfrβ), riċettaturi tal-fatturi ta’ l-iżvilupp ta’ l-endotilju vaskulari (vegfr1, vegfr2 uvegfr3), riċettatur tal-fattur taċ-ċellola ta’ l-għerq (kit), fms-like tyrosine kinase-3 (flt3), riċettaturi tal-fattur li jistimula l- kolonji (csf-1r), u r-riċettatur tal-fattur newrotropiku li ġej minn razza taċ-ċelloli glijali (ret).